Compare AbbVie Inc (ABBV) vs Lucid Group Inc (LCID) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Lucid Group (LCID) trades at $5.995, down 1.4% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 deliveries of 3,093 vehicles, missing expectations, alongside a leadership overhaul. Financially, LCID shows severe losses with a net income margin of -239.81% in 2025 and negative cash flow from operations of -$2.93B, though revenue grew to $1.35B.

The outlook remains challenging due to persistent losses and high cash burn, but the consensus price target of $11.75 suggests potential upside if execution improves. Key risks include ongoing class-action lawsuits, competitive pressures in the EV market, and reliance on Saudi funding. Investors should weigh the high-risk profile against long-term growth prospects in electric vehicles.